NCT05887479 is a Phase 4 clinical trial of Botulinum toxin type A in Cerebrovascular Disorders, sponsored by Sisli Hamidiye Etfal Training and Research Hospital.

Who is sponsoring NCT05887479?

NCT05887479 is sponsored by Sisli Hamidiye Etfal Training and Research Hospital.

What drugs are being tested in NCT05887479?

Interventions in NCT05887479: Botulinum toxin type A, %0,9 NaCl.

What condition does NCT05887479 study?

NCT05887479 studies Cerebrovascular Disorders, Spasticity, Muscle, Botulinum Toxin.

Is NCT05887479 still recruiting?

NCT05887479 is currently withdrawn. Last updated 22 November 2023.

Last reviewed 2023-11-22 · How we verify

NCT05887479

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity

Withdrawn Phase 4 Last updated 22 November 2023

What this trial tests

Phase 4 trial testing Botulinum toxin type A in Cerebrovascular Disorders. Withdrawn.

Timeline

25 May 2023

Primary endpoint
15 July 2023

15 August 2023

Quick facts

Lead sponsor	Sisli Hamidiye Etfal Training and Research Hospital
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Start date	25 May 2023
Primary completion	15 July 2023
Estimated completion	15 August 2023

Drugs / interventions tested

Botulinum toxin type A (BOTULINUM TOXIN TYPE A) — full drug profile →
%0,9 NaCl

Conditions studied

Cerebrovascular Disorders — all drugs for Cerebrovascular Disorders →
Spasticity, Muscle — all drugs for Spasticity, Muscle →
Botulinum Toxin — all drugs for Botulinum Toxin →

Sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Who can join

Adults 35 to 80, any sex, with Cerebrovascular Disorders or Spasticity, Muscle. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The patients between the ages of 35-80 who developed spasticity in the upper extremity after stroke will be included.. Botulinum toxin(BT-A) injection will be applied to the study group(n=16) and placebo injection to the control group(n=15) in addition to conventional rehabilitation and stretching exercises. Evaluations will be made before the treatment, in the 2nd week, and in 3rd month after the treatment. Pain relief will be evaluated with the Visual Analog Scale(VAS) and spasticity assessment will be done with the Modified Ashworth Scale(MAS). The functionality will be evaluated with Fugl Meyer Assessment Scale(FMAS) and Box Block Test(BBT).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Botulinum toxin type A

Trials testing the same drug.

NCT07236632 — Hyaluronic Acid vs Botulinum Toxin Injection in Treatment of Lifelong Drug-Resistant Premature Ejaculation: Randomized S · NA · not yet recruiting
NCT06448676 — Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides · Phase 4 · not yet recruiting
NCT06296082 — Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Sp · Phase 2, PHASE3 · recruiting
NCT06385171 — Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation · recruiting
NCT06465056 — Use of Botulinum Toxin A in Direct Eyebrow Lift Scar · Phase 2 · recruiting

Other recruiting trials for Cerebrovascular Disorders

Currently open trials in the same condition.

NCT07185022 — Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion · NA · recruiting
NCT07324278 — Hybrid Stroke Rehab With Mirror Priming · NA · recruiting
NCT06954610 — Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation · recruiting
NCT07167550 — The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke · Phase 3 · recruiting
NCT07140601 — Environmental Pollutants and Neurological Disorders · recruiting

Other Sisli Hamidiye Etfal Training and Research Hospital trials

Trials by the same sponsor.

NCT07334002 — The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus · NA · not yet recruiting
NCT07321041 — Effect of Delivery Time on Umbilical Cord Blood Gas Parameters in Cesarean Sections Under General and Spinal Anesthesia · recruiting
NCT07476690 — Effect of rESWT Session Frequency on Spasticity and Function Assessed by Sonoelastography in Children With Cerebral Pals · NA · recruiting
NCT07166614 — Dexmedetomidine vs Propofol in High-Risk ERCP Patients · NA · recruiting
NCT07250243 — Turkish Validation and Reliability of the John Hopkins In-Room Independence Scale · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05887479 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sisli Hamidiye Etfal Training and Research Hospital
Last refreshed: 22 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05887479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing